Evaluation of XRCC1 Gene Polymorphism as a Biomarker in Head and Neck Cancer Patients Undergoing Chemoradiation Therapy.
CONCLUSIONS: Polymorphic variant XRCC1 HNSCC patients treated with CCRT have significantly increased acute radiation morbidities and may have a trend toward better PFS in comparison with the wild variant. PMID: 29893275 [PubMed - in process]
Publication date: Available online 1 April 2020Source: Journal of Molecular LiquidsAuthor(s): Xianting Xie, Lu Zhang, Wenjuan Zhang, Reza Tayebee, Atefe Hoseininasr, Hamid H. Vatanpour, Zeinab Behjati, Suying Li, Marjan Nasrabadi, Liuyi Liu
Publication date: Available online 1 April 2020Source: Carbohydrate PolymersAuthor(s): Chia-Hsiang Yen, Sheng-Tien Li, Nai-Chen Cheng, You-Ren Ji, Jyh-Horng Wang, Tai-Horng Young
Publication date: Available online 1 April 2020Source: Inorganica Chimica ActaAuthor(s): Sourav De, S.K. Ashok Kumar
Publication date: Available online 1 April 2020Source: European Polymer JournalAuthor(s): Himani Kalita, Manoj Patowary
Conclusion: CD26 is involved in the pathogenesis of colorectal diseases; sCD26 is diminished in CRC patients suggesting the potential utility of a sCD26 for diagnosis. PMID: 32223519 [PubMed - as supplied by publisher]
Publication date: Available online 2 April 2020Source: Urology Case ReportsAuthor(s): Makoto Isono, Kenji Seguchi, Masanori Yamanaka, Kosuke Miyai, Kazuki Okubo, Keiichi Ito
Publication date: Available online 2 April 2020Source: Preventive MedicineAuthor(s): Francesca Holme, Jose Jeronimo, Francisco Maldonado, Claudia Camel, Manuel Sandoval, Benito Martinez-Granera, Mirna Montenegro, Jacqueline Figueroa, Rose Slavkovsky, Kerry A. Thomson, Silvia de Sanjose, the Scale-Up project team
Publication date: Available online 1 April 2020Source: Preventive MedicineAuthor(s): Shelton J. Bartley, Vicki Benard, Eric Tai, Tanner Rockwell, Kristy Kenney, Lisa C. Richardson
Two University of Rochester physicians — one as an investigator and one as a patient — had major roles in a cutting-edge clinical trial using the body’s own immune cells to fight late-stage cancer. The striking results, showing that 93 percent of the study patients responded to the treatment, were reported in the April 2, 2020, iss ue of New England Journal of Medicine.
Publication date: Available online 2 April 2020Source: The American Journal of SurgeryAuthor(s): Zhi Ven Fong, David C. Chang, Chin Hur, Ginger Jin, Angela Tramontano, Naomi M. Sell, Andrew L. Warshaw, Carlos Fernandez del Castillo, Cristina R. Ferrone, Keith D. Lillemoe, Motaz Qadan
More News: Cancer | Cancer & Oncology | Carcinoma | Dermatitis | Dermatology | Gastroschisis Repair | Genetics | Head and Neck Cancer | HNSCC | International Medicine & Public Health | Laryngeal Cancer | Oral Cancer | Oral Cavity Cancer | Pharyngeal Cancer | Physics | Radiation Therapy | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology | WHO